English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 851810      Online Users : 1092
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3613


    Title: Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant
    Authors: Huang, MH;Huang, CY;Lien, SP;Siao, SY;Chou, AH;Chen, HW;Liu, SJ;Leng, CH;Chong, P
    Contributors: Vaccine Research and Development Center
    Abstract: Purpose: To enhance the water affinity of W/O emulsion-adjuvanted vaccines, we used three bioresorbable polymers named PEG-b-PLA, PEG-b-PCL, and PEG-b-PLACL as hydrophilic emulsifier to stabilize the interfaces between the oily Montanide ISA 51 adjuvant and the antigen media. Methods: Polymers were synthesized by ring-opening polymerization of lactide and/or ε-caprolactone in the presence of monomethoxy PEG. 1H NMR and GPC data showed that obtained polymers consisted of 70 wt.% hydrophilic PEG block and 30 wt.% lipophilic PLA, PCL, PLACL block with molecular weights of 7,000. Results: The polymer-stabilized ISA51 emulsions have high affinity to water, such that the stock of antigen-encapsulating emulsion could be re-dispersed into PBS before injection, thus yielding stable and injectable W/O/W emulsion nanoparticles. Immunogenicity studies showed that PEG-b-PLACL/ISA51/PBS-formulated ovalbumin with only 5% of ISA51 oily adjuvant could induce the same level of antibody titers as those induced by PBS/ISA51-formulated ovalbumin. Conclusions: The novel multi-phase emulsions increase fluidity and conceptually diminish local reactions with respect to the W/O type vaccines produced from the same oil. These features are of great interest for applications in candidate vaccine delivery, especially for further optimization of alternative immunization routes, such as intramuscular, transdermal or mucosal administration.
    Date: 2009-08
    Relation: Pharmaceutical Research. 2009 Aug;26(8):1856-1862.
    Link to: http://dx.doi.org/10.1007/s11095-009-9898-y
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0724-8741&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000267685800007
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67650032608
    Appears in Collections:[莊再成] 期刊論文
    [冷治湘] 期刊論文
    [劉士任] 期刊論文
    [陳信偉] 期刊論文
    [黃明熙] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP67650032608.pdf267KbAdobe PDF740View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback